On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...

Are you a houseplant lover? Can’t get enough green, leafy plants? We have some exciting news for you. A French startup called Neoplants recently launched a bioengineered houseplant designed to clean ...

The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular trauma in the extremities of adults. The one-time, single-use therapy -- the ...

The Mayo Foundation for Medical Education and Research, the nonprofit parent entity of the Mayo Clinic, is a worldwide research powerhouse that is assigned scores of U.S. patents each year. Mayo ...

How synthetic biology is enabling bio-based alternatives for industrial processes, sustainable food systems, and breakthroughs in healthcare. The role of advanced gene-editing tools like CRISPR-Cas9 ...

A new type of bioengineered blood vessel showed strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...

The Grande Ronde Hospital (GRH) Wound Clinic, located at 700 Sunset Dr., Suite F, has experienced significant growth over the past 15 years, evolving from a single-room clinic in the SurgiCenter that ...

– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into ...

Approvals can now begin on what are termed “negative claims” on labels for meat, poultry and egg products that do not contain bioengineered ingredients or that are derived from livestock that do not ...